Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
GSK 4-component Strep A vaccine + AS37
- Development stage
- Unknown
- Lead developer
- GSK
- Modality
- Split/Subunit Vaccines → Inactivated Vaccines → Prophylactic Vaccines → Vaccines & Immunotherapeutics, Recombinant Proteins and Enzymes
- Administration
- Intramuscular
01
Overview
The GSK 4-component Strep A vaccine is a recombinant protein-based and glycoconjugate vaccine developed by GSK for the prevention of Group A Streptococcal (Streptococcus pyogenes) infections. The vaccine formulation consists of three recombinant proteins—streptolysin O (SLO), Streptococcus pyogenes adhesion and division protein (SpyAD), and S. pyogenes cell envelope protease (SpyCEP)—alongside a glycoconjugate comprising the Group A carbohydrate (GAC) conjugated to a recombinant CRM197 carrier protein. This specific formulation is adjuvanted with AS37, a proprietary GSK adjuvant system containing a Toll-like receptor 7 (TLR7) agonist (LHD153R) adsorbed to aluminum hydroxide. The vaccine is designed to provide broad protection against Strep A by targeting multiple conserved antigens and stimulating a balanced Th1/Th2 immune response. It is currently being evaluated in Phase 1 clinical trials for safety, reactogenicity, and immunogenicity in healthy adults.
- Other names
- GSK 4-component Strep A vaccineGSK4-component Strep A vaccineGSK-4-component Strep A vaccineStrep A vaccine with AS37 adjuvant
02
Targets
SpyCEP (Streptococcus pyogenes cell envelope protease)SLO (Streptolysin O)GAC (Group A carbohydrate antigen)SpyAD (Streptococcus pyogenes adhesion and division protein)
Beyond the preview
Go deeper on GSK 4-component Strep A vaccine + AS37.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on GSK 4-component Strep A vaccine + AS37.